Literature DB >> 23725007

Utilization of genetic testing prior to subspecialist referral for cerebellar ataxia.

Brent L Fogel1, Barbara G Vickrey, Jenny Walton-Wetzel, Eli Lieber, Carole H Browner.   

Abstract

OBJECTIVE: To evaluate the utilization of laboratory testing in the diagnosis of cerebellar ataxia, including the completeness of initial standard testing for acquired causes, the early use of genetic testing, and associated clinical and nonclinical factors, among a cohort referred for subspecialty consultation.
METHODS: Data were abstracted from records of 95 consecutive ataxia patients referred to one neurogenetics subspecialist from 2006-2010 and linked to publicly available data on characteristics of referral clinicians. Multivariable logistic and linear regression models were used to analyze unique associations of clinical and nonclinical factors with laboratory investigation of acquired causes and with early genetic testing prior to referral.
RESULTS: At referral, 27 of 95 patients lacked evidence of any of 14 laboratory studies suggested for initial work-up of an acquired cause for ataxia (average number of tests=4.5). In contrast, 92% of patients had undergone brain magnetic resonance imaging prior to referral. Overall, 41.1% (n=39) had genetic testing prior to referral; there was no association between family history of ataxia and obtaining genetic testing prior to referral (p=0.39). The level of early genetic testing was 31.6%, primarily due to genetic testing despite an incomplete laboratory evaluation for acquired causes and no family history. A positive family history was consistently associated with less extensive laboratory testing (p=0.004), and referral by a neurologist was associated with higher levels of early genetic testing.
CONCLUSIONS: Among consecutive referrals to a single center, a substantial proportion of sporadic cases had genetic testing without evidence of a work-up for acquired causes. Better strategies to guide decision making and subspecialty referrals in rare neurologic disorders are needed, given the cost and consequences of genetic testing.

Entities:  

Mesh:

Year:  2013        PMID: 23725007      PMCID: PMC3732434          DOI: 10.1089/gtmb.2013.0005

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  17 in total

1.  Do malpractice concerns, payment mechanisms, and attitudes influence test-ordering decisions?

Authors:  G L Birbeck; D R Gifford; J Song; T R Belin; B S Mittman; B G Vickrey
Journal:  Neurology       Date:  2004-01-13       Impact factor: 9.910

Review 2.  Diagnosis and management of early- and late-onset cerebellar ataxia.

Authors:  E Brusse; J A Maat-Kievit; J C van Swieten
Journal:  Clin Genet       Date:  2007-01       Impact factor: 4.438

3.  Long-term effects of an education programme on the optimal use of clinical chemistry testing in primary health care.

Authors:  Mirja Mindemark; Anders Larsson
Journal:  Scand J Clin Lab Invest       Date:  2009       Impact factor: 1.713

4.  An approach to the patient with late-onset cerebellar ataxia.

Authors:  Brent L Fogel; Susan Perlman
Journal:  Nat Clin Pract Neurol       Date:  2006-11

Review 5.  Clinical features and molecular genetics of autosomal recessive cerebellar ataxias.

Authors:  Brent L Fogel; Susan Perlman
Journal:  Lancet Neurol       Date:  2007-03       Impact factor: 44.182

6.  Association of specialist involvement and quality of care for Parkinson's disease.

Authors:  Eric M Cheng; Kari Swarztrauber; Andrew D Siderowf; Mahmood S Eisa; Martin Lee; Stefanie Vassar; Erin Jacob; Barbara G Vickrey
Journal:  Mov Disord       Date:  2007-03-15       Impact factor: 10.338

Review 7.  Childhood cerebellar ataxia.

Authors:  Brent L Fogel
Journal:  J Child Neurol       Date:  2012-07-04       Impact factor: 1.987

8.  Do neurologists and primary care physicians agree on the extent of specialty involvement of patients referred to neurologists?

Authors:  Kari Swarztrauber; Barbara G Vickrey
Journal:  J Gen Intern Med       Date:  2004-06       Impact factor: 5.128

Review 9.  Cerebellar ataxias.

Authors:  Mario Manto; Daniele Marmolino
Journal:  Curr Opin Neurol       Date:  2009-08       Impact factor: 5.710

Review 10.  Ataxias with autosomal, X-chromosomal or maternal inheritance.

Authors:  Josef Finsterer
Journal:  Can J Neurol Sci       Date:  2009-07       Impact factor: 2.104

View more
  6 in total

1.  Genetics: Utility of next-generation sequencing in ataxias.

Authors:  Eng-King Tan
Journal:  Nat Rev Neurol       Date:  2013-10-15       Impact factor: 42.937

Review 2.  Clinical exome sequencing in neurologic disease.

Authors:  Brent L Fogel; Saty Satya-Murti; Bruce H Cohen
Journal:  Neurol Clin Pract       Date:  2016-04

3.  Exome sequencing in the clinical diagnosis of sporadic or familial cerebellar ataxia.

Authors:  Brent L Fogel; Hane Lee; Joshua L Deignan; Samuel P Strom; Sibel Kantarci; Xizhe Wang; Fabiola Quintero-Rivera; Eric Vilain; Wayne W Grody; Susan Perlman; Daniel H Geschwind; Stanley F Nelson
Journal:  JAMA Neurol       Date:  2014-10       Impact factor: 18.302

4.  The need to develop a patient-centered precision medicine model for adults with chronic disability.

Authors:  Susan M Wolf; Bharat Thyagarajan; Brent L Fogel
Journal:  Expert Rev Mol Diagn       Date:  2017-04-03       Impact factor: 5.225

Review 5.  Clinical exome sequencing in neurogenetic and neuropsychiatric disorders.

Authors:  Brent L Fogel; Hane Lee; Samuel P Strom; Joshua L Deignan; Stanley F Nelson
Journal:  Ann N Y Acad Sci       Date:  2015-08-06       Impact factor: 5.691

6.  A diagnostic ceiling for exome sequencing in cerebellar ataxia and related neurological disorders.

Authors:  Kathie J Ngo; Jessica E Rexach; Hane Lee; Lauren E Petty; Susan Perlman; Juliana M Valera; Joshua L Deignan; Yuanming Mao; Mamdouh Aker; Jennifer E Posey; Shalini N Jhangiani; Zeynep H Coban-Akdemir; Eric Boerwinkle; Donna Muzny; Alexandra B Nelson; Sharon Hassin-Baer; Gemma Poke; Katherine Neas; Michael D Geschwind; Wayne W Grody; Richard Gibbs; Daniel H Geschwind; James R Lupski; Jennifer E Below; Stanley F Nelson; Brent L Fogel
Journal:  Hum Mutat       Date:  2019-11-25       Impact factor: 4.700

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.